Tag: Premas Biotech
Premas Biotech wins Gates Foundation grant to advance thermostable rabies vaccine
Funding to support early-stage development of innovative rabies vaccine for low- and middle-income countries
India Unlimited 3.0: Experts say India has the Talent, Tech, and...
With end-to-end capabilities, India is rapidly scaling up its global presence in discovery, development, and manufacturing
FACE TO FACE: Dr Prabuddha Kundu, Managing Director, Premas Biotech
Dr Prabuddha Kundu, Co-founder & Managing Director, Premas Biotech recently on the sidelines of Global Bio India 2024 in New Delhi shared his insights on his company focus on global collaborations, industry's key growth drivers, India's US$ 300 billion bioeconomy target by 2030 and much more.
Premas Biotech appoints Saumen Chakraborty to its Board
Saumen Chakraborty is the Managing Director of Samarjita Management Consultancy. He retired as the President and Chief Financial Officer of Dr Reddy’s in 2020
Digitally powered smart labs are the future of biopharma R&D: Experts
Leading biopharmaceutical scientists and industry leaders shared their valuable insights at the e-Conference on ‘Digital Laboratories: The Emerging Era of High-Tech R&D’ organized by BioVoice News on March 30, 2022
Premas Biotech gets approval to initiate phase 1 trials in South...
Premas Biotech has licensing deal for virus-like particle (VLP) injectable vaccine technology for COVID-19, with Oravax for commercialization in India..................
Premas Biotech & Oramed announce oral COVID-19 vaccine candidate that produces...
With triple antigen targeting, the vaccine is claimed to offer better protection against COVID-19 variants. While Oravax Medical Inc has been established to accelerate the vaccine’s path to market, clinical trials are expected to commence in Q2 2021......................
Premas Biotech’s COVID-19 vaccine shows encouraging results, human trials shortly
Triple-antigen COVID-19 vaccine candidate, PRAK-03202, produces neutralizing immune response in animal studies; Premas Biotech in talks with regulatory authorities for next steps................
Premas Biotech SARS-Cov-2 vaccine candidate moves ahead for animal trials
The four-week placebo-controlled, blinded and randomized tests to be conducted in mice will seek to evaluate safety and examine immune response dose titration in the rodent model................
COVID-19: Premas Biotech tries multi-antigenic approach to develop a vaccine
The triple antigen vaccine being developed by Premas Biotech is being designed to try to overcome presently known and possible future mutations of novel coronavirus...................